All News

knee.oa_.jpg (keep)

Methotrexate Fails in Knee Osteoarthritis

d MedPage Today

We'll be blunt: methotrexate flopped in a randomized placebo-controlled trial among patients with osteoarthritis (OA) of the knee.

Contrary to results from a previous trial in hand OA, the old-line disease-modifying anti-rheumatic drug (DMARD) failed to bring any improvement relative to placebo in either pain or an objective measure of joint inflammation after a year of treatment, according to Changhai Ding, PhD, MD, of Southern Medical University in Guangzhou, China, and colleagues.

Read Article
Rogers video cover

Type 2 SLE: Insights from a Biopsychosocial Framework

d Jennifer L. Rogers, MD

Many of the common symptoms of lupus - fatigue, nociplastic pain, brain fog - can be invisible and difficult to measure, and can often co-occur with impaired sleep, depression and anxiety. These symptoms have led to a well described discordance between physician and patient perception of lupus activity and flares, and this discordance can impact communication, trust, medication adherence, and ultimately outcomes. We developed the Type 1 and Type 2 model many years ago as a means to bridge this gap.

Read Article
osteoporosis.OP_.Drugs_.jpg

Denosumab and Osteoporosis - A JAMA Review

d Jack Cush, MD

An overview of denosumab use in osteoporosis (OP)  by Bauer and Ensrud was published in JAMA. 

Read Article
Kamen

Rules on Mycophenolate Use in SLE

d Diane Kamen, MD, MSCR

Dr. Diane Kamen. a rheumatologist and lupologist from the Medical University of South Carolina in Charleston, South Carolina, discusses the use of mychophenolate in the management of systemic lupus. 

Read Article
SLE Treatment Landscape: Abundance or Overload? Imagine a world where the multiple drugs in Phase 2 and 3 trials actually get approved, and we get access to them? I know you may be thinking that I am overly optimistic, but there are so many drugs in development in lupus that we https://t.co/1SsSMqfZWz
Dr. John Cush RheumNow ( View Tweet)
Moneyball Rheumatology (5.30.2025) Dr. Jack Cush reviews the book/movie, "Moneyball" and a suggests moneyball strategy is needed to find next level responses for our patients. https://t.co/c79y9UNTcQ https://t.co/at7mDderOP

Links:

Dr. John Cush RheumNow ( View Tweet)
Sacroiliitis is a rare adverse reaction of isotretinoin. Review of 67 pts finds median age 21 yrs, onset median 2.5 mos (0-24) post isotretinoin. Sxs: LBP 70%) & hip pain 45%. Dx by MRI (73%) w BME. Full recovery 81% isoretinoin D/C & NSAIDs (< 10% biologics)

Dr. John Cush RheumNow ( View Tweet)

PPACMAN Consensus Recs. for CV risk in PSO/PSA published for Rheums/Derms/PCPs - check BP, Wt, Lipids, Cr. - Look for HTN, DM, smoking, obesity, metabolic synd. - Risk stratify w/ hsCRP, Lipids - Lifestyle management https://t.co/MkgYopTNAX https://t.co/6yyxVIxpC0

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of ARF & Post-streptococcal reactive arthritis (PSRA) following Group A strept infxn. Early Dx & Rx of Strept can prevent ARF & PSRA. PSRA is a sterile arthritis, bimodal age onset, lower extrem arthritis, usually resolves without lasting sequelae https://t.co/ld208yf0Zk

Links:

Dr. John Cush RheumNow ( View Tweet)

JAK inhibitors reduce inflammation while potentially exacerbating the propagation viral infections. They suppress transcription of IFN-stimulated genes in non-infected cells (usually triggered by type I IFNs produced by infected cells) Thus facilitating viral propagation https://t.co/zOOTf7e1Hj
Dr. John Cush RheumNow ( View Tweet)
MMWR: 1994 the U.S. Vaccines for Children program has covered the cost of vaccines for US children. Since 1994 routine child vaccinations will have prevented ~508 million illness, 32 million hospitalizations, & 1,129,000 deaths,; direct savings of $540 billion & societal savings https://t.co/CBUojpR3Q8
Dr. John Cush RheumNow ( View Tweet)
Single center study of 1538 #SLE pts found 2.2% w/ lupus mesenteric vasculitis (LMV) - 39 LMV episodes in 31 pts - 2/3 had Nausea, vomiting, diarrhea & abdominal pain (~15% peritoneal irritation) & had active Dz (renal, Skin, Heme). LMV responded to steroids & https://t.co/vXCpbiC60P
Dr. John Cush RheumNow ( View Tweet)
Lupus Unlocked: Survey Responses https://t.co/LQs7VKT6lq https://t.co/F7yqQvSvvZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus Unlocked: Pregnancy and SLE In this webinar, panelists discussed issues such as congenital heart block, lupus nephritis treatment, teratogenic risks including conception on mycophenolate, antiphospholipid syndrome, hypertension management including the differential https://t.co/0RfAH7jW0J
Dr. John Cush RheumNow ( View Tweet)
Are PSO pts also Rx for PSA? Registry study of 17,310 PSO pts (19% also w PsA). @ baseline Biologics used in 44% of PSO, but higher rate in PSO+PsA (66% vs 39% PSO). 9.4% of PSO+PsA pts on Rx approved for PSO, but not explicitly for PsA. https://t.co/jMqk6gm1RR https://t.co/CQnwYO9yRO

Links:

Dr. John Cush RheumNow ( View Tweet)
Do SGLT2 and GLP-1 therapies have a role in Lupus? Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA), initially developed to lower glucose in Type 2 Diabetes, also provide cardiovascular and renal protection for patients https://t.co/8JEfcv2BUz
Dr. John Cush RheumNow ( View Tweet)
Belimumab in SLE with Mucocutaneous or Vasculitis Findings A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care. https://t.co/BlYWKLJPdb

Links:

Dr. John Cush RheumNow ( View Tweet)

Valves Gone Wild in SLE Lupus valvulitis is a rare cardiac manifestation of active systemic lupus erythematosus (SLE) and is defined by inflammation of one or more cardiac valves. It is often associated with Libman-Sacks endocarditis (LSE), which is characterized by the https://t.co/XcC2POFDRd
Dr. John Cush RheumNow ( View Tweet)
2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. https://t.co/2NFwTllLZa https://t.co/Q6smp1ZVH2

Links:

Dr. John Cush RheumNow ( View Tweet)
IMPACT Study - Certolizumab Efficacy in APS Pregnancies A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to https://t.co/776CTvvGfb
Dr. John Cush RheumNow ( View Tweet)
×